Role of cytochrome P450 2E1 in the metabolism of acrylamide and acrylonitrile in mice

被引:270
作者
Sumner, SCJ
Fennell, TR
Moore, TA
Chanas, B
Gonzalez, F
Ghanayem, BI
机构
[1] Chem Ind Inst Toxicol, Res Triangle Pk, NC 27709 USA
[2] NIEHS, Res Triangle Pk, NC 27709 USA
[3] NCI, Bethesda, MD 20892 USA
关键词
D O I
10.1021/tx990040k
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Acrylonitrile (AN) and acrylamide (AM) are commonly used in the synthesis of plastics and polymers. In rodents, AM and AN are metabolized to the epoxides glycidamide and cyano-ethylene oxide, respectively. The aim of this study was to determine the role of cytochrome P450 in the metabolism of AM and AN in vivo. Wild-type (WT) mice, WT mice pretreated with aminobenzotriazole (ABT, 50 mg/kg ip, 2 h pre-exposure), and mice devoid of cytochrome P450 2E1 (P450 2E1-null) were treated with 50 mg/kg [C-13]AIM po. WT mice and P450 2E1-null mice were treated with 2.5 or 10 mg/kg [C-13]AN po. Urine was collected for 24 h, and metabolites were characterized using C-13 NMR. WT mice excreted metabolites derived from the epoxides and from direct GSH conjugation with AM or AN. Only metabolites derived from direct GSH conjugation with AM or AN were observed in the urine from ABT-pretreated WT mice and P450 2E1-null mice. On the basis of evaluation of urinary metabolites at these doses, these data suggest that P450 2E1 is possibly the only cytochrome P450 enzyme involved in the metabolism of AM and AN in mice, that inhibiting total P450 activity does not result in new pathways of non-P450 metabolism of AM, and that mice devoid of P450 2E1 do not excrete metabolites of AM or AN that would be produced by oxidation by other cytochrome P450s. P450 2E1-null mice may be an appropriate model for the investigation of the role of oxidative metabolism in the toxicity or carcinogenicity of these compounds.
引用
收藏
页码:1110 / 1116
页数:7
相关论文
共 37 条
[1]   Comparative Toxicokinetics of 2,3-C-14- and 1-C-14-acrylonitrile in the Rat [J].
Ahmed, E. Ahmed ;
Farooqui, Mohammed Y. H. ;
Upreti, Raj K. ;
El-Shabrawy, Osama .
JOURNAL OF APPLIED TOXICOLOGY, 1983, 3 (01) :39-47
[2]  
BARFKNECHT TR, 1988, ENV MOL MUTAGEN S11, V11, pR30
[3]  
BAUS DK, 1983, EPA600882007F
[4]   The metabolism and pharmacokinetics of acrylamide: Implications for mechanisms of toxicity and human risk estimation [J].
Calleman, CJ .
DRUG METABOLISM REVIEWS, 1996, 28 (04) :527-590
[5]   ACRYLAMIDE - ITS METABOLISM, DEVELOPMENTAL AND REPRODUCTIVE EFFECTS, GENOTOXICITY, AND CARCINOGENICITY [J].
DEARFIELD, KL ;
ABERNATHY, CO ;
OTTLEY, MS ;
BRANTNER, JH ;
HAYES, PF .
MUTATION RESEARCH, 1988, 195 (01) :45-77
[6]   URINARY METABOLITES OF [1,2,3-C-13]ACRYLONITRILE IN RATS AND MICE DETECTED BY C-13 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY [J].
FENNELL, TR ;
KEDDERIS, GL ;
SUMNER, SCJ .
CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (06) :678-687
[7]  
GHANAYEM BI, 1999, IN PRESS J PHARM EXP
[8]   ROLE OF HUMAN CYTOCHROME-P-450-IIE1 IN THE OXIDATION OF MANY LOW-MOLECULAR-WEIGHT CANCER SUSPECTS [J].
GUENGERICH, FP ;
KIM, DH ;
IWASAKI, M .
CHEMICAL RESEARCH IN TOXICOLOGY, 1991, 4 (02) :168-179
[9]   MUTAGENICITY OF ACRYLAMIDE AND ITS ANALOGS IN SALMONELLA-TYPHIMURIUM [J].
HASHIMOTO, K ;
TANII, H .
MUTATION RESEARCH, 1985, 158 (03) :129-133
[10]   BIOCHEMICAL STUDIES ON ACRYLAMIDE, A NEUROTOXIC AGENT [J].
HASHIMOTO, K ;
ALDRIDGE, WN .
BIOCHEMICAL PHARMACOLOGY, 1970, 19 (09) :2591-+